Michael Alvarado, M.D. is a Professor of Surgery and member of the breast care and melanoma programs. Just recently, he was appointed Accountable Care Medical Director. Dr. Alvarado received his undergraduate degree from Arizona State University, his master’s degree in chemistry from the University of Arizona and his medical degree from Dartmouth Medical School.
After completing his residency at Dartmouth-Hitchcock Medical Center, he completed his surgical oncology fellowship at the H. Lee Moffitt Cancer Center & Research Institute at the University of South Florida.
Dr. Alvarado plays an integral role in the multidisciplinary breast care team at the Carol Franc Buck Breast Care Center in the UCSF Helen Diller Family Comprehensive Cancer Center. He is also Director of the Breast Surgical Oncology Fellowship Program.
Professor John Benson is a Consultant Breast Surgeon at Addenbrooke’s Hospital, Cambridge, Affiliated Assistant Professor, University of Cambridge and Visiting Professor, School of Medicine, Anglia Ruskin University. He has previously been actively involved with the San Antonio Breast Cancer Symposium as a member of the Planning Committee and Career Development Forum (2011–2015). He has published more than 160 papers (including 30 in the Lancet/Lancet Oncology) and written/edited 8 books. He is currently ranked in the top 0.076% of breast cancer experts worldwide (Expertscape). He was elected Honorary Secretary of the Association of Breast Surgery in 2023.
John Benson 1st March 2024
Paula Briggs, UK
Mr Henry J Cain MBChB (hons) FRCS, MD
Henry Cain qualified in 2001 from Leicester Medical School. Following the award of MD in breast cancer signalling pathways and higher surgical training in Newcastle upon Tyne he spent a year as the Oncoplastic Fellow at the Canniesburn Unit in Glasgow. He was appointed a Consultant Oncoplastic Surgeon at the Royal Victoria Infirmary Newcastle upon Tyne in 2013. Driving improvements in surgical care he has led the introduction of Radioactive Seed Localisation of impalpable breast cancer and post neo-adjuvant chemotherapy I125 seed Targeted Axillary Dissection to the UK. With a significant recruitment into national trials he is the surgical lead Co-Investigator for the NOSTRA trial and the Chief Investigator for the PRE-DX national RCT.
David Cameron, UK
Dr. Julia Camps-Herrero is a breast radiologist and also the Head of the Radiology Department at University Hospital de la Ribera in Alzira (Valencia). Since 1999 she is an active researcher in multimodality breast radiology, with a special interest in MRI. Dr Camps-Herrero is an active speaker in Latin America and Europe, where she has been invited in more than 270 presentations. She is the author of 19 papers, 7 book chapters and 75 scientific posters and oral presentations. She is the current Breast section editor for EURORAD since 2007, has been chairman of the ECR 2012 Breast Subcommittee and of the Spanish Senology Congress in 2015, member of the Programme Planning Committee for ECR 2015 and 2016. Presently, she is the Vice-president of SEDIM (Spanish Breast Imaging Society) and President of the European Society of Breast Imaging (EUSOBI).
Miss Leena Chagla is the President of the Association of Breast Surgery and the past President of the Liverpool and Northwest Society of Surgeons. She heads the breast unit at Mersey and West Lancashire Teaching Hospitals which is actively involved in clinical innovation and trials. She continues to publish regularly in peer reviewed journals.
Leena qualified from Grant Medical College, Mumbai, with a gold medal in Surgery. Whilst in India, she trained at the Sir JJ Hospital and at the Tata Memorial Cancer Centre. Her passion for surgical oncology developed in those formative years.
She is a popular speaker both nationally and internationally and is involved in the development of guidelines for the management of breast cancer. She is passionate about MDT working and the welfare of trainees. She launched the Anti-bullying Campaign (#CoreItOut) for ABS in alliance with RCSEd. She represented ABS on the pathology Big 18 and the organising committee of Symposia Mammographicum.
Leena was instrumental in setting up the International Forum at ABS with a view to sharing good practice globally. She is committed to improving and standardising Breast cancer care through education and training. She is an Educational Supervisor for the National Oncoplastic Fellow for the last 20 years and she has trained international trainees from LMICs on the MTI scheme since 2018. She represented Liverpool and Northern Counties in water-polo, and she enjoys all sport.
Dr John Conibear graduated from the University Hospital of Wales in 2001 and completed his post-graduate general medical training in The Barts and The London Training rotation in 2006.
Before gaining his substantive post as a consultant clinical oncologist in St. Bartholomew’s Hospital in 2014, he completed a 2-year fellowship with the NCRI Radiotherapy Trials Quality Assurance Group in Mount Vernon Hospital. During his fellowship he conducted research into techniques to improve clinician target outlining during radiotherapy planning and was subsequently awarded a MD(Res) from UCL in 2018.
Dr Conibear is currently the clinical director for thoracic and neuro-oncology in St. Bartholomew’s Hospital and, the oncology clinical lead for the National Lung Cancer Audit (NLCA).
Dr Conibear specialises in all the non-surgical treatments for both breast and lung cancers and has a specialist interest in stereotactic radiotherapy. He is trained in using the ViewRay MRIdian MRI-guided linac, Accuray Cyberknife and Leksell Icon Gamma Knife platforms for delivering both intra- and extra-cranial stereotactic radiotherapy.
Dr. Javier Cortes received a degree in Medicine and Surgery from the Universidad Autónoma de Madrid in 1996. He continued his studies at the University of Navarra, specialising in Medical Oncology at the Clínica Universitaria de Navarra, where he continued as Assistant in the Department of Oncology from 2002. He was Associated Professor of Oncology in the Faculty of Medicine at the University of Navarra during that period. Dr. Cortés was awarded the title of Doctor in Medical Oncology from the University of Navarra in 2002. Since 2003, he has worked in the Department of Medical Oncology at the Hospital Vall d’ Hebron, Barcelona, where he is Coordinator of the Teaching and Training Programme for Residents in Oncology and Senior Specialist in the Area of Breast Cancer with a special interest in New Drugs Development. Dr. Cortés is Head of the Breast Cancer Unit and the Melanoma Unit.
In addition, he has two masters’ degree: “Medical Direction and Clinical Management” by the Universidad Nacional de Educación a Distancia (UNED) and “Research methodology in Health Sciences” by the Universidad Autonoma de Barcelona and a degree in “Statistics in Health Sciences” by the Universidad Autonoma de Barcelona.
Dr. Cortes is the author of more than 100 publications, especially about breast tumours and new drugs and more than 250 communications at different conferences. He actively participates in the development of numerous national and international clinical investigations, especially in relation to drugs directed against molecular targets and new chemotherapy agents, and he is an ad hoc reviewer of various oncology journals.
Dr Cortés is an active member of the Spanish, European, and American Societies of Medical Oncology (SEOM, ESMO, ASCO), a member of the Scientific Committee of the European Society of Medical Oncology and the Scientific Committee of SOLTI group.
Ramsey Cutress is Professor of Breast Surgery in Southampton, topic advisor for the NICE Breast Cancer Guidelines and co-director of the Association of Breast Surgery (ABS) Advanced Skills in Breast Disease Management Course. Clinical research interests include breast cancer in young women as a member of the POSH study research team, and investigation of patient and host determinants of breast cancer outcomes including genetic predisposition, immunological and lifestyle factors. He is lead investigator for the HTA funded EndoNET neo-adjuvant endocrine therapy trial, and breast sub-specialty editor for the Annals of the Royal College of Surgeons of England.
Rajiv Dave, UK
Dr. Richard De Boer completed his basic medical and oncology training at the Royal Melbourne Hospital and then in 1997 undertook a 3-year breast and lung cancer clinical research fellowship at the Royal Marsden Hospital in London, working with Professor Ian Smith.
He returned to Melbourne in 2000 and since then has been a consultant medical oncologist working in both public and private practice. His primary areas of clinical interest are in breast and lung cancer, with breast cancer interests focusing on endocrine therapy and mechanisms of resistance, treatment-induced bone loss and bone metastases, and biological predictors of response/survival. He is actively involved in clinical research, and is a member of the Australian New Zealand Breast Cancer Trials Group, and head of the Breast Trials group of Cancer Trials Australia. He has authored or co-authored articles appearing in journals such as the Journal of Clinical Oncology, Annals of Oncology, The Breast and British Journal of Cancer.
Professor Mike Dixon is a Consultant Breast Surgeon at the Edinburgh Breast Unit, and Clinical Director of the Breast Cancer Now Research Group in Edinburgh and holds an Honorary Professorship in Breast Surgery at the University of Edinburgh. In 2013 he received an OBE from HRH The Queen for his work improving our understanding and management of breast disease. He has published over 330 papers, contributed 130 book chapters, and written or edited 25 books. He has given over 200 invited lectures, was the Royal College of Surgeons of Australasia Visiting Fellow in 2000 and 2011, and was visiting Professor to Yale and Harvard in 2012.
Michael Douek, UK
Sarah Downey is first consultant post in Bradford for 4 years and moved to East Anglia in 2005. Undertook Divisional Director role in own hospital for 5 years – opened new daycase unit. Acted as regional Breast Screening QA Surgeon for 6 years. Joined General Surgery SAC in 2015 and became regional TPD in 2018. Currently General Surgery virtual training programme director; Undergraduate PBL tutor; online tutor for oncoplastic MS. Honorary Associate Professor UEA and Clinical Appraisal Lead. Former TIG Chair and faculty on Advanced Breast Cancer Course. Currently Vice President of ABS.
Kenneth Elder is currently a consultant breast surgeon at the Western general hospital in Edinburgh where he is the breast lead for the University of Edinburgh ChM qualification.
He undertook his undergraduate medical training at the University of Nottingham qualifying in 2008. At the end of his medical career he travelled to East Timor to work as a disaster relief doctor and was awarded The Worshipful Society of Apothecaries of London prize for Conflict and Catastrophe Medicine. He completed his higher surgical training in Edinburgh and surrounding hospitals. During his training he completed a research fellowship at the Peter Macallum Cancer Research Centre in Melbourne Australia under Professor Bruce Mann and Professor Iain Campbell looking at the efficacy of modern breast screening and the genetics of pre-cancerous breast disease. For his time there he was awarded the Ethicon travelling scholarship. This research has been published widely and has been presented around the world. He returned to Australia to complete a clinical fellowship under Professor Bruce Mann at the Royal Women’s Hospital of Melbourne. Mr. Elder is also an invited member of the teaching faculty at the Royal College of Surgeons of Hong Kong.
Kathryn Ellis, UK
Matthew J. Ellis, USA
Prof D. Gareth Evans , MB, BS, MD, FRCP, FLSW, FRCOG, ad eundem
A Consultant at Manchester University Hospitals NHS Foundation Trust and The Christie NHS Foundation Trust, Professor Evans has established a national and international reputation in clinical and research aspects of cancer genetics, particularly in neurofibromatosis, schwannomatosis and breast cancer. Professor Evans is a chair of medical genetics and cancer epidemiology at the University of Manchester. He has published 1060 peer reviewed research publications, 355 as first or senior author as well as over 150 reviews, letters and chapters. In the last eight years he has raised over £75 million in grants for multicentre and local studies. He is Chief Investigator on two NIHR program grants on breast cancer risk prediction and also has an NIHR RfPB grant as CI (2011). He has led a successful bid for a Nationally funded NF2 service (£7.5 million pa) that started in 2010 and is involved in the national complex NF1 service. He is the cancer prevention early detection theme leader on the NIHR Manchester Biomedical Research Centre. Professor Evans is also lead clinician on the NICE Familial Breast Cancer Guideline Group.
Professor Evans is recognised as the international leader in the genetics and epidemiology of Neurofibromatosis type 2 and his ground-breaking research on mosaicism and mortality has had a major impact on treatment of this serious inherited condition. The National Highly Specialised Service for NF2 he leads pioneered use of the drug bevacizumab which along with multidisciplinary care has already improved survival and quality of life for this life-limiting condition. In 2013 he led the team that identified SMARCE1 as the cause of the related condition hereditary clear cell meningioma. Work in Gorlin syndrome led to the discovery of SUFU as a cause of Gorlin syndrome that has redefined the risks of the associated childhood brain cancer, medulloblastoma (SUFU~30%; PTCH1~2%). He is an emeritus two term NIHR Senior Investigator and has published widely (H-index-118 Web of Science; 161-Google) and is Cancer Prevention theme lead on the all-Manchester BRC and is frequently invited as a keynote speaker to scientific conferences at home/abroad. He is now co-lead on the Manchester CR-UK ICED Alliance Early detection initiative. He was a moving force of the Prevent Breast Cancer Appeal which helped establish the first dedicated breast cancer prevention centre in Europe (https://preventbreastcancer.org.uk/about-us/the-nightingale-centre/) and has been a trustee of five charities including Breast Cancer Now (previously chairman of the Scientific Advisory Board) and the Neuro Foundation.
Mr Douglas Ferguson attended St George’s University of London, in 1990 was awarded BSc (Hons) and completed MBBS, with merits, in 1993. He was awarded FRCS (England) in 1997 and Master of Surgery in 2005. Also in 2005 Douglas was the UK and Ireland Gold medal winner for Intercollegiate FRCS on completion of his training. He was appointed as the Royal Devon & Exeter’s first Oncoplastic Breast Surgeon in April 2006. He completed a PGCert in medical education 2018.
His current roles at the RDE and nationally include; Clinical Lead Breast Services (Surgery and Radiology); the PI for multiple International Trials, – ARB, LORIS, PALLET, MAMMO50, POSNOC, POETIC, IBISII, FH01 FH02, ATNEC, POETIC A, SMALL, IMPARTER and CANDO3. He is a Breast Tutor for Royal College of Surgeons of England, faculty for the National Oncoplastic Fellowships and Master of Oncoplastic Surgery Degree and an Honorary Associate Professor for the University of Exeter Medical School. He is also the Association of Breast Surgery rep for the National Breast Trainee Interface Group for the Oncoplastic Breast Fellowship. Douglas is the Chairman South West for the Oncoplastic Breast Surgeons (SWOBS) group and convenor of its course. He is a University Representative for RD&E and Royal College Representative for Consultant Appointment Committees and is also a Peninsular Doctors Mentor. He is the current Honorary Treasurer Association of Breast Surgery.
Mr Ferguson is also Chairman of West Hill Wasps Junior Football; coaches under 14’s team and is the club’s Welfare officer. In his spare time he plays local league football and continues to learn the guitar!
Adam Gilmour is a Consultant Plastic Surgeon / Oncoplastic Breast Surgeon at the Canniesburn Plastic Surgery Unit in Glasgow.
At the end of training he completed one of the Nationally appointed Trainee Interface Group (TIG) fellowships in Oncoplastic Breast Surgery. He subsequently served as the BAPRAS representative on the Oncoplastic TIG committee for two years.
He offers all aspects of breast reconstruction but also performs oncology procedures. He is a member of the breast cancer MDT for NHS Ayrshire & Aaron and believes in collaborative working and ensuring exceptional patient care.
Amit Goyal is a Consultant Oncoplastic Breast Surgeon, Associate Professor, and Clinical Lead of Breast Surgery at University Hospitals of Derby & Burton NHS Foundation Trust. His research focuses on axillary management in breast cancer and breast reconstruction. As Chief Investigator, he leads major UK breast cancer surgical trials, including POSNOC and ATNEC, investigating axillary treatment. Additionally, he leads the BIOSYM trial, comparing synthetic and biological matrices in breast reconstruction.
Dr. Stephen R. Grobmyer, MD, is the Institute Chair of the Oncology Institute at Cleveland Clinic Abu Dhabi. Prior to joining Cleveland Clinic Abu Dhabi, Dr. Grobmyer was Professor of Surgery, Section Head of Breast Surgery and Co-Director of the Cleveland Clinic Comprehensive Breast Cancer Program at Cleveland Clinic Main Campus in Cleveland, Ohio, USA.
Dr. Grobmyer received his medical degree from the University of Texas Southwestern Medical School in Dallas, Texas and completed his residency in General Surgery at New York Hospital-Cornell Medical Center in New York. He completed a fellowship in Surgical Oncology at Memorial Sloan Kettering in 2004.
Dr. Grobmyer’s innovative clinical care and research focuses on developing new approaches to prevent, diagnose and treat breast cancer. He has published over 200 peer-reviewed manuscripts and 20 book chapters. Additionally, he has given over one hundred invited lectures nationally and internationally.
Dr. Grobmyer has been the recipient of numerous prestigious awards including, The Lester Dragstedt Physician Scientist Award, The Society of Surgical Oncology Clinical Investigator Award and The American College of Surgeons Japan Travelling Fellowship. He is a member of the American Surgical Association. His influential clinical care and research has been featured widely in the Unites States media including NBC Nightly News, MSNBC, National Public Radio, The New York Times and Vogue.
Stephen Harrow, UK
Tracey Irvine has been a Consultant Oncoplastic Surgeon in Guildford since 2009. She has a special interest in oncoplastic breast conservation, neoadjuvant chemotherapy and management of the axilla and runs the Guildford gene carrier clinic for patients in the KSS region. In 2015 she was awarded the Murray Brennan Scholarship by the American College of Surgeons and spent two months in the major cancer centres in the US. She has been Senior Clinical advisor for the breast Getting it Right First Time (GIRFT) programme since 2017 and is CQC Specialty Advisor for breast, setting up the new breast specialty specific inspection. In 2022 she was appointed National Clinical Lead for Breast Cancer.
Kevin Kalinsky, M.D., M.S. is Professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine. Dr. Kalinsky serves as the director of the Glenn Family Breast Center at Winship, as well as the Director of the Division of Medical Oncology at Emory.
Cliona Kirwan, UK
Ian MacPherson, UK
Mr Andy Malyon FRCS(Plast)
Consultant Plastic Surgeon
Professional Advisor to Medical Devices & Legislation Unit Scottish Government
National Clinical Lead, Scan for Safety
Synopsis and Biography:
After 20 years as a consultant plastic surgeon with an interest in breast reconstruction and oncoplastic surgery at the Canniesburn Unit in Glasgow, he has now reduced his clinical sessions to one day of oncoplastic work at Gartnavel General Hospital. The remainder of his time is split between working for the Medical Devices & Legislation Unit in Scottish Government, and the Scottish Scan for Safety Programme delivered by National Service Scotland.
Prof. Bruce Mann is Professor of Surgery at the University of Melbourne and Director of The Breast Service at the Royal Melbourne and Royal Women’s Hospital in Melbourne. He is on the council of Breast SurgANZ, the Scientific Advisory Committee of the ANZ Breast Cancer Trials Group and is past president of the Clinical Oncology Society of Australia. He has been involved in many clinical trials and much clinical and translational research regarding breast cancer, with his main research interest being tailoring treatment to the disease and the patient.
James Mansell, UK
Cameron Martin, UK
Yazan Masannat is a Consultant Oncoplastic Breast Surgeon at Aberdeen Royal Infirmary and one of the Associate Post Graduate Deans at NHS Education for Scotland. He is an Honorary Senior Clinical Lecturer at the University of Aberdeen and an E-Tutor with the University of East Anglia. He is on the Board of Trustees of the Association of Breast Surgery, a member of their education and training committee and the meetings secretary. He is also on the Education and training committee for the European Society of Surgical Oncology. He is the communications lead at the iBRA-net in addition to being an examiner at the European Board of Surgical Oncology and the European Board of Breast Surgery exams (UEMS)
Yazan has more than 60 publications and has been awarded numerous research grants including the prestigious NRS Fellowship award by the Chief Scientist Office (CSO) in Scotland. This is to continue research on Novel MRI techniques in Breast Surgery with the Team at the University of Aberdeen which he does on top of his clinical work.
Yazan is also the creator of www.iBreastBook.com which is a free online resource with contributions from many of the leading Breast and Plastic surgeons across the world. The iBreastBook Webinar series, which he started during the covid pandemic with the support of colleagues has been a huge international success.
Stuart McIntosh is Professor of Surgical Oncology at Queen’s University in Belfast, and a consultant oncoplastic breast surgeon at Belfast City Hospital.
Stuart is an experienced clinical trialist, with a particular interest in neoadjuvant, peri-surgical and treatment de-escalation studies, and is Chief Investigator for the UK SMALL trial, as well as holding surgical leadership roles in several other trials. He is also one of the Royal College of Surgeons Surgical Specialty Leads for Breast Surgery, responsible for supporting the development and delivery of breast cancer surgical trials nationally. Additionally, he chairs the Northern Ireland Cancer Trials Network, responsible for the delivery of cancer trials across the five cancer hospitals in Northern Ireland. Stuart’s laboratory research interests include the DNA damage driven immune response in breast cancer.
Dr. Olga Oikonomidou is an Academic Consultant Medical Oncologist specializing in breast cancer and Breast Cancer Translational Research Group Leader at the Institute of Genetics and Cancer, University of Edinburgh. Other than a degree in Medicine, she holds a BSc in Human Genetics, MSc in Oncology, MRes in Immunology and a PhD in translational medicine. Her responsibilities are split between running a busy breast oncology practice and leading on a large portfolio of clinical trials and breast cancer translational studies. Dr Oikonomidou is a clinical expert for NICE and SMC and has been involved in numerous technology appraisals since 2015. She has received several prestigious grants for her clinical research projects. She is on the TMG of numerous national and international trials. She is currently the global Chief Investigator of 2 multinational multicentre clinical trials, UK Chief Investigator of 4 clinical trials and the PI for more than 50 trials. Her academic research interest is focused on prediction of biomarkers of response to treatment and clinical trials in breast cancer in all phases.
Carlo Palmieri, UK
Marina Parton, UK
Ann Partridge, USA
Sarah E Pinder is Chair of Breast Pathology at King’s College London and Lead Breast Pathologist at Guy’s & St Thomas’ Hospitals.
She Chairs the National Coordinating Committee for Breast Pathology (NCCBP) for the Royal College of Pathologists & the UK NHS Breast Screening Programme. She is President of the Association of Breast Pathology.
She is pathologist for the low risk DCIS trial (LORIS), OPTIMA, MAMMO50, SMALL, NOSTRA and EndoNET trials, amongst others.
Her translational research interests are focused on in situ breast carcinoma, but include a wide range of collaborative work.
She has published over 350 articles in the peer-reviewed literature, and over 100 invited articles and chapters in textbooks.
Shelley Potter PhD FHEA FRCS
Shelley Potter is Professor of Surgical Oncology at Bristol Medical School and Consultant Oncoplastic Breast Surgeon at North Bristol NHS Trust.
Her research interests focus on improving outcomes for women with breast cancer through the development and delivery of high-quality patient-centred research. She is an experienced researcher who had led several national and international collaborative oncoplastic and reconstructive breast surgical projects including the iBRA and TEAM studies and is currently Chief Investigator for Brighter, ANTHEM and Pre-BRA. Recent work has focused on optimisation of breast cancer treatment.
Her leadership national roles include Royal College of Surgeons of England Surgical Specialty Lead for Breast Surgery, Chair of iBRA-NET and Secretary to the British Breast Group.
Dr Alistair Ring is a Consultant Medical Oncologist at The Royal Marsden. He undertook his pre-clinical training at the University of Cambridge and clinical training at the University of Oxford, qualifying in 1997. His oncology training was based at The Royal Marsden, St George’s and Guy’s Hospitals, London. He gained his MD research degree in 2005 from the Institute of Cancer Research (ICR) at the University of London.
In 2008 he was appointed as Senior Lecturer in Oncology at Brighton and Sussex Medical School and in 2014 he was appointed Consultant Medical Oncologist at The Royal Marsden.
He has a major interest in research and is UK lead for a number of research studies examining the roles of aspirin and modern targeted drugs in the management of breast cancer. He is Chair of the Committee for Clinical Research at The Royal Marsden and the ICR.
In 2018 Dr Ring was appointed Honorary Reader in Breast Cancer Clinical Trials, at the Institute of Cancer Research.
Laszlo Romics, UK
Dr Allison Rose MBBS, MMed, FRANZCR
Director, Northwestern BreastScreen
Head, The Royal Melbourne & The Women’s Hospital Breast Imaging Service
Associate, University of Melbourne Radiology Department
Dr Allison Rose was appointed at The Royal MelbourneHospital as one of the original
radiologists with the Victorian Pilot breast cancer screening program in 1989
and became Director ofNorthwestern BreastScreen in 1999. In 2009 she became Head of Breast Imaging for The
Royal Melbourne Hospital and Womens Hospital Breast Service. She established Breast MRI & MRI guided biopsy for the service and since 2015, CEM. She is a keen educator having launched Melbourne Breast MRI Intensive interactive workstation based Courses in 2011. These are now cloud based have been expanded to include CEM. Her research interests include de-escalation of breast cancer treatment, tailored screening for breast cancer, and breast cancer staging and surveillance.
Sarah Savaridas, UK
Dr. Karla Sepulveda is a Professor of Radiology at Baylor College of Medicine and Medical Director of Breast Imaging at Baylor St. Luke’s Medical Center in Houston. TX. She holds the Pat Korell Endowed Professorship of Breast Imaging. Dr. Sepulveda completed her fellowship in Breast Imaging at MD Anderson Cancer Center. She is active in the American College of Radiology and Texas Radiological Society and uses this work to advocate for high value, multidisciplinary care for breast cancer patients. Her areas of professional interest include healthcare innovation, the role of radiology in precision oncology, and applications of artificial intelligence in breast imaging.
Dr. Nisha Sharma is a consultant breast radiologist and Director of the Breast Screening program Leeds/Wakefield. She is active in research involving new technologies, artificial intelligence and improving the patient pathway. She is a professional clinical advisor for breast screening and NHS England.
Richard Simcock, UK
Prof. Alastair Thompson graduated from the University of Edinburgh, UK with Distinction in Surgery and subsequently trained as a Clinician Scientist and Fellow of the Royal College of Surgeons of Edinburgh. In 2014 he moved from the position of Professor of Surgical Oncology, Clinical Lead for the Dundee Cancer Centre/Experimental Cancer Medicine Centre and Foundation Director of the Clinical Research Centre, Dundee, UK to the Department of Surgical Oncology, The University of Texas, MD Anderson Cancer Center in Houston, Texas, specializing in breast cancer.
Achievements to date include setting up and chairing the Breast Cancer Campaign Breast Tissue Bank Board for the UK and Eire, leading the 12,000 patient UK National Audit of Screen Detected DCIS and, for 5 years to 2014, chairing the UK National Cancer Research Institute, Breast Clinical Studies Group (with oversight of 120 academic and commercial clinical studies in breast cancer). He actively contributes to a range of clinical trials in the prevention, early detection and therapy of breast cancer. He remains as UK Chief Investigator for a number of key trials including MINDACT, MA32 and SOLE and continues to chair the data monitoring committees and trials steering groups for several phase II drug trials and phase III surgical trials respectively in the UK.
Active in translational laboratory research, he built a breast cancer research program over 15 years in Dundee, including a xenograft program and tissue banking facility with a focus on the p53 network and drug development. He has successfully supervised 20 PhD or research MD students and currently has 4 students completing PhDs. The impact of over 200 peer reviewed research papers has included global firsts demonstrating the effect of drugs in vivo in animal models and in human cancers.
He continues to provide leadership in trials and clinical translational research with colleagues in Europe and Australasia while establishing clinical trials and laboratory collaborations in the US, through membership of the American Society of Clinical Oncology, American Association of Cancer Research, South West Oncology Group and Translational Breast Cancer Research Consortium.
Arran K. Turnbull, UK
Mark Verrill, UK
Dr Raghavan Vidya is a Senior lecturer at Birmingham University and Consultant Oncoplastic breast surgeon at the Royal Wolverhampton NHS Trust. She graduated from University of Madras, India followed by Postgraduate training in General Surgery. She completed her MD (Research) on aromatase inhibitors from University of Edinburgh. She has introduced and mentored new innovations including muscle-sparing implant-based breast reconstruction.
She serves as a Trustee of the Association of Breast surgery and actively contributes to its working. Dedicated to teaching and training, she contributes actively as a Higher Surgical Trainer, delivers lectures, and runs workshops as invited faculty for national and international meetings. Through her role as Royal College, International Surgical Training Programme Lead for Breast Surgery, she is committed to advancing breast training. She has a strong focus towards clinical research exemplified by over 150 publications. She has published two books on breast reconstruction and an ebook on Global Breast Training in collaboration with RCS and ABS. She promotes clinical application of Genomics in NHS as Associate Director of Genomics in West Midlands. She is actively involved in clinical trials and have a special interest in new technology and advances in breast surgery.
Lynda Wyld, MB,ChB, PhD, FRCS, FEBS
Lynda Wyld underwent surgical training in the UK, spending time in Sheffield, Nottingham and Manchester. She did her PhD at the University of Sheffield. She was appointed to an academic post at the University of Sheffield in 2002 and is now Professor of Surgical Oncology. Her clinical interest is the management of breast cancer and she practices as a Consultant Oncoplastic Breast Surgeon at Doncaster Teaching Hospitals in the UK. Her main research interest is in age related inequalities in cancer surgery where she has led projects to improve outcomes and develop decision aids for older women with breast cancer. Her other career focus has been to develop training in cancer surgery and in particular to see the development of breast surgery. She has been a member of BASO since 1997, winning the Raven Prize in 1998, joining the board of Trustees in 2010, becoming secretary in 2012 and President between 2015 and 2017. She is also past chair of the education and training committee of ESSO (2012-2018) and is the current secretary and president elect of the UEMS European Breast Examination Board. She is a trustee of the ABS.